At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GNLX Genelux Corporation
Market Closed 12-20 16:00:00 EST
2.27
+0.08
+3.65%
High2.31
Low2.15
Vol63.00K
Open2.16
D1 Closing2.19
Amplitude7.31%
Mkt Cap77.42M
Tradable Cap58.50M
Total Shares34.10M
T/O141.14K
T/O Rate0.24%
Tradable Shares25.77M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.